{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T04:16:21Z","timestamp":1777954581476,"version":"3.51.4"},"reference-count":12,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:p>Published data concerning the semiology of neuroborreliosis at FDG PET\/CT is scarce, and most reported cases with acute onset of neurological symptoms did not exhibit significant metabolic abnormalities. This 60-year-old man with follicular lymphoma achieved a complete response after 6 cycles of R-CHOP. Two weeks after the last injection, he developed afebrile headaches, neck pain, and paresthesia in his fingers, later followed by a brutal left peripheral facial palsy. FDG PET\/CT demonstrated an increased metabolism of the cerebellum and of the cervical spinal cord, which completely resolved after treatment with doxycycline for 3 weeks. This is the first case report exhibiting serial metabolic changes at FDG PET\/CT in the central nervous system during the evolution of the disease. This case illustrates the risks of lympho-depletion in patients treated with rituximab and highlights the value of PCR for Borrelia in the CSF in patients with false-negative Borrelia serology.<\/jats:p>","DOI":"10.1097\/rlu.0000000000006077","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T02:00:18Z","timestamp":1753840818000},"page":"e380-e383","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Serial FDG PET\/CT Findings in a Patient With Seronegative Neuroborreliosis After Treatment With Rituximab for a Follicular Lymphoma"],"prefix":"10.1097","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5606-8467","authenticated-orcid":false,"given":"Cl\u00e9ment","family":"Drouet","sequence":"first","affiliation":[{"name":"Nuclear Medicine Department, Centre Georges Fran\u00e7ois Leclerc"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loup","family":"Guichard","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Department, Centre Georges Fran\u00e7ois Leclerc"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amandine","family":"Durand","sequence":"additional","affiliation":[{"name":"Hematology Department"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeanne","family":"Godon","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Schneider","sequence":"additional","affiliation":[{"name":"Neurology Department, University Hospital Fran\u00e7ois Mitterrand, Dijon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,7,28]]},"reference":[{"key":"R1-20260504","doi-asserted-by":"crossref","first-page":"R136","DOI":"10.1186\/cc10254","article-title":"Meningitis in adult patients with a negative direct cerebrospinal fluid examination: value of cytochemical markers for differential diagnosis","volume":"15","author":"Viallon","year":"2011","journal-title":"Crit Care"},{"key":"R2-20260504","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nrneurol.2015.121","article-title":"Lyme neuroborreliosis-epidemiology, diagnosis and management","volume":"11","author":"Koedel","year":"2015","journal-title":"Nat Rev Neurol"},{"key":"R3-20260504","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s15010-007-6121-0","article-title":"Seronegative Lyme neuroborreliosis in a patient on treatment for chronic lymphatic leukemia","volume":"35","author":"Harrer","year":"2007","journal-title":"Infection"},{"key":"R4-20260504","doi-asserted-by":"crossref","first-page":"bcr2012007627","DOI":"10.1136\/bcr-2012-007627","article-title":"Seronegative Lyme neuroborreliosis in a patient using rituximab","volume":"2013","author":"van Dop","year":"2013","journal-title":"BMJ Case Rep"},{"key":"R5-20260504","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1186\/s12879-018-3273-8","article-title":"Case report: persistently seronegative neuroborreliosis in an immunocompromised patient","volume":"18","author":"Wagemakers","year":"2018","journal-title":"BMC Infect Dis"},{"key":"R6-20260504","doi-asserted-by":"crossref","first-page":"645298","DOI":"10.3389\/fneur.2021.645298","article-title":"Case report: Borrelia-DNA revealed the cause of arthritis and dermatitis during treatment with rituximab","volume":"12","author":"Sj\u00f6wall","year":"2021","journal-title":"Front Neurol"},{"key":"R7-20260504","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12941-022-00506-6","article-title":"An unexpected case of Borrelia garinii liver infection","volume":"21","author":"Duffau","year":"2022","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"R8-20260504","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1136\/pn-2023-003976","article-title":"Rituximab leading to an atypical presentation of neuroborreliosis and false negative serology","volume":"24","author":"Lorentzen","year":"2024","journal-title":"Pract Neurol"},{"key":"R9-20260504","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3201\/eid3102.240777","article-title":"Borrelia spielmanii-associated neuroborreliosis in patient receiving rituximab, Belgium","volume":"31","author":"Carette","year":"2025","journal-title":"Emerg Infect Dis"},{"key":"R10-20260504","doi-asserted-by":"crossref","first-page":"11795735241247026","DOI":"10.1177\/11795735241247026","article-title":"CXCL13 as a biomarker in the diagnostics of European lyme Neuroborreliosis\u2014a prospective multicentre study in Austria","volume":"16","author":"Wai\u00df","year":"2024","journal-title":"J Cent Nerv Syst Dis"},{"key":"R11-20260504","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3390\/ijms25010425","article-title":"CXCL13 in cerebrospinal fluid: clinical value in a large cross-sectional study","volume":"25","author":"Erhart","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R12-20260504","doi-asserted-by":"crossref","first-page":"e213330","DOI":"10.1212\/WNL.0000000000213330","article-title":"Pearls & Oy-sters: recurrent Lyme neuroborreliosis with seroreversion in a patient with multiple sclerosis on a B-cell depleting therapy","volume":"104","author":"Dersch","year":"2025","journal-title":"Neurology"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006077","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T19:01:03Z","timestamp":1777921263000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,28]]},"references-count":12,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006077","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,28]]},"assertion":[{"value":"2025-04-01","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-25","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}